Vascular Dementia Report Insights
What is Vascular Dementia?
Vascular Dementia is a decline in thinking skills caused by conditions that block or reduce blood flow to various regions of the brain, depriving them of oxygen and nutrients. Inadequate blood flow can damage and eventually kill cells anywhere in the body, but the brain is especially vulnerable.
How will Vascular Dementia market change in upcoming years?
The increase in Vascular Dementia market size is a direct consequence of increasing prevalent population of Vascular Dementia patients in the 7MM. Vascular Dementia market size shall grow during the forecast period owing to the increase in government initiatives, extensive research and development activities of pharmaceutical companies launch of upcoming therapies.
According to DelveInsight, Vascular Dementia market in 7MM is expected to change in the study period 2017-2030.
Currently, there is no US Food and Drug Administration (FDA)- approved treatments for Vascular Dementia thus, treatment strategies have largely focused on the control of underlying vascular risk actors and associated symptoms. Many vascular risk factors are modifiable, such as lifestyle choices, including physical exercise, diet, alcohol consumption, and smoking.
Pharmacological agents for the treatment of Vascular Dementia remain limited. Several medications approved by the FDA for the treatment, such as memantine or acetylcholinesterase inhibitors, can offer a modest benefit in Vascular Dementia. Further treatment interventions are discussed below.
Progress in the development of therapies for Vascular Dementia has been difficult because of uncertainties over disease classification and diagnostic criteria, controversy over the exact nature of the relation between cerebrovascular pathology and cognitive impairment, and the paucity of identifiable tractable treatment targets. Potential treatments are in clinical trials, including calcium channel blockers, and other agents targeting endothelial function or the renin angiotensin system are putative candidates for further clinical trials.
Management of vascular dementia should focus on identifying and managing comorbidities, ensuring that vascular risk factors are optimally managed, ensuring appropriate recognition and management of non-cognitive symptoms, and appropriate psychosocial and other support to optimise quality of life for patients.
For more information on Vascular Dementia market share, click here @ https://www.delveinsight.com/report-store/vascular-dementia-market
Which companies are in Vascular Dementia pipeline?
Vascular Dementia emerging drugs landscape does not represent a particularly promising picture due to the lack of late-stage clinical products, which is quite evidently based on the scarcity of clinical trials being conducted. There are few therapies such as SaiLuoTong (SLT) capsule (Shineway Pharmaceutical Group Co., Ltd), Prospecta (Materia Medica Holding) etc. that are being developed for Vascular Dementia, however these therapies are not considered in DelveInsight’s forecast model based on the fact that it mainly focuses on the therapies being developed in the 7 major markets i.e. (United States, Germany, France, Italy, Spain, United Kingdom and Japan).
Brexpiprazole is a molecule discovered by Otsuka and co-developed by Otsuka and Lundbeck. Brexpiprazole is an orally available dopamine receptor D2 partial agonist. This quinolinone derivative is a successor to aripiprazole (Abilify, Aripiprex), an approved, widely used drug that is also a dopamine D2 receptor partial agonist. Brexpiprazole is being developed worldwide as an add-on therapy primarily for the treatment of depression and schizophrenia, but also for agitation and other behavioral symptoms in patients with Alzheimer's disease. In addition, it is being tested in people with bipolar and post-traumatic stress disorder. The drug was approved in the U.S. on July 10, 2015, as an adjunctive therapy to antidepressants in adults with major depressive disorder and as a treatment in adults with schizophrenia. It is currently being evaluated in phase III study for treatment of dementia.
Discovered by Eisai, E2027 is a selective phosphodiesterase (PDE) 9 inhibitor. Inhibiting PDE9 reduces the degradation of cyclic GMP (cGMP) which is critical to signal transmission among cells, and helps maintain the concentration of cGMP in the brain. Eisai is currently developing E2027 as a new treatment for dementia with Lewy bodies. It is currently being evaluated in a phase II study which is expected to be completed by 2025.
Expected launch of emerging therapies, is expected to create a significant impact on the market size during the forecast period (2020-2030)
To know more on Vascular Dementia Companies @ https://www.delveinsight.com/report-store/vascular-dementia-pipeline-insight